Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. VSports app下载.

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2019 May 8;19(1):427.
doi: 10.1186/s12885-019-5617-1.

Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer

Rafał Suwinski  1 , Monika Giglok  2 , Katarzyna Galwas-Kliber  2 , Adam Idasiak  2 , Bozena Jochymek  3 , Regina Deja  4 , Barbara Maslyk  4 , Jolanta Mrochem-Kwarciak  4 , Dorota Butkiewicz  5
Affiliations

Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer

Rafał Suwinski (VSports最新版本) et al. BMC Cancer. .

Abstract

Background: Several studies have documented that blood biomarkers can improve basic prognostic models in radiotherapy and radio-chemotherapy for non-small cell lung cancer. The current study evaluated the prognostic impact of six markers focusing on their utility in homogenous subsets, compared to the significance in a large heterogeneous group. VSports手机版.

Methods: Blood samples of 337 patients who were referred for curative or palliative external beam thoracic radiotherapy for non-small cell lung cancer were collected. The concentration of osteopontin (OPN), vascular endothelial growth factor (VEGF), erythropoetin (EPO), high mobility group box 1 protein (HMGB1), insulin-like growth factor 1 (IGF-1) and platelet-derived growth factor (PDGF) in serum were measured by ELISA assay and the prognostic potential was assessed using univariable and multivariable survival models. V体育安卓版.

Results: Multivariable analysis revealed that out of several variables studied six dichotomized features: namely: cigarette smoking, lack of chemotherapy, palliative doses of radiotherapy, high OPN concentration, advanced T stage and high VEGF concentration had a highly significant (p < 0. 005) and independent influence on overall survival in the group of 337 patients. In a subset of patients treated with curative radio-chemotherapy or radiotherapy (N = 148) tumor pathology, EPO concentration and VEGF concentration, significantly and independently influenced overall survival. In a subset of patients with squamous cell cancer (N = 206) OPN had a highly significant impact on overall survival. In contrast, in a subset of patients with nonsquamous histology (N = 131) only VEGF had a significant influence on survival. V体育ios版.

Conclusions: Blood serum proteins appear to be clinically useful prognosticators of overall survival in radio-chemotherapy and radiotherapy for non-small cell lung cancer VSports最新版本. In unselected heterogeneous groups, dichotomized concentrations of OPN and VEGF emerged among the strongest independent prognosticators of overall survival. VEGF and EPO concentration (dichotomized) were found to be independent prognostic factors among the patients treated with curative doses of radiotherapy. The utility of OPN as a prognostic marker appeared restricted to the patients with squamous histology. .

Keywords: Biomarkers; Erythropoetin; High mobility group box 1 protein; Insulin-like growth factor 1; Lung cancer; Osteopontin; Platelet-derived growth factor; Radiotherapy; Survival; Vascular endothelial growth factor. V体育平台登录.

PubMed Disclaimer

Conflict of interest statement (VSports最新版本)

Ethics approval and consent to participate

The study was approved by the local Bioethical Committee at Center Oncology M VSports注册入口. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch. Written informed consents were provided by all patients.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Overall survival in the heterogeneous group of patients with non-small cell lung cancer, depending on number of 6 independent risk features (cigarette smoking, lack of chemotherapy, palliative doses of radiotherapy, high OPN concentration, advanced T stage and high VEGF concentration). Missing data were deleted (n = 227). The differences between the patients with 0–1, 2–4 and 5–6 risk features are highly significant (p < 0.00001)
Fig. 2
Fig. 2
Influence of tumor pathology (a), EPO concentration (b) and VEGF concentration (c) on overall survival in a group of 148 patients with non-small cell lung cancer treated with curative radio-chemotherapy or radiotherapy. The differences in overall survival are highly significant (p = 0.005; p = 0.008; p = 0.006 in groups a, b, c respectively). Median EPO and VEGF concentration was selected as a cut-off
Fig. 3
Fig. 3
Influence of OPN concentration on overall survival in a group of 171 patients with squamous-cell cancer (a) and 44 patients with adenocarcinoma (b). The difference in overall survival according to biomarker concentration is highly significant among the patients with squamous cell cancer (p < 0.0001), but not among the patients with adenocarcinoma. 0.18
See this image and copyright information in PMC

References

    1. Syrigos K, Fiste O, Charpidou A, Grapsa D. Circulating tumor cell count as a predictor of survival in lung cancer. Crit Rev Oncol Hematol. 2018;25:60–68. doi: 10.1016/j.critrevonc.2018.03.004. - DOI - PubMed
    1. Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, Ferrari G, Annessi V, Lasagni D, Carbonelli C, et al. Circulating plasma DNA as a diagnostic biomarker in non-small cell lung cancer. Lung Cancer. 2009;64(1):92–97. doi: 10.1016/j.lungcan.2008.07.012. - DOI - PubMed
    1. Suwinski R, Klusek A, Tyszkiewicz T, et al. Gene expression from bronchoscopy obtained tumour samples as a predictor of outcome in advanced inoperable lung cancer. PLoS One. 2012;7(7):e41379. doi: 10.1371/journal.pone.0041379. - DOI - PMC - PubMed
    1. Thunnisen E, van der Oord K, Bakker M. Prognostic and predictive biomarkers in lung cancer: a review. Virchows Arch. 2014;464(3):347–358. doi: 10.1007/s00428-014-1535-4. - DOI - PubMed
    1. Xu-Welliver M, Carbone DP. Blood-based biomarkers in lung cancer: prognosis and treatment decisions. Transl Lung Cancer Res. 2017;6(6):708–712. doi: 10.21037/tlcr.2017.09.08. - DOI - PMC - PubMed

Publication types

MeSH terms